Autolus Therapeutics’ (AUTL) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a $10.00 target price on the stock.

A number of other research analysts also recently commented on AUTL. Wells Fargo & Company dropped their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a report on Friday, March 21st. Truist Financial decreased their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $9.32.

Autolus Therapeutics Trading Down 1.4%

AUTL opened at $2.12 on Thursday. The stock’s 50-day moving average price is $1.55 and its 200 day moving average price is $1.95. Autolus Therapeutics has a 12-month low of $1.11 and a 12-month high of $5.00. The firm has a market cap of $564.22 million, a price-to-earnings ratio of -1.75 and a beta of 1.76.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The business had revenue of $8.98 million during the quarter, compared to the consensus estimate of $1.59 million. On average, research analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Several hedge funds have recently modified their holdings of the business. Two Sigma Investments LP raised its holdings in Autolus Therapeutics by 23.8% during the fourth quarter. Two Sigma Investments LP now owns 906,767 shares of the company’s stock worth $2,131,000 after purchasing an additional 174,485 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Autolus Therapeutics by 146.7% in the fourth quarter. Renaissance Technologies LLC now owns 618,942 shares of the company’s stock valued at $1,455,000 after acquiring an additional 368,071 shares during the last quarter. Handelsbanken Fonder AB boosted its holdings in Autolus Therapeutics by 30.9% in the fourth quarter. Handelsbanken Fonder AB now owns 73,300 shares of the company’s stock valued at $172,000 after acquiring an additional 17,300 shares during the last quarter. Legal & General Group Plc boosted its holdings in Autolus Therapeutics by 392.0% in the fourth quarter. Legal & General Group Plc now owns 297,736 shares of the company’s stock valued at $697,000 after acquiring an additional 237,224 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Autolus Therapeutics by 91.6% during the fourth quarter. Millennium Management LLC now owns 1,653,241 shares of the company’s stock worth $3,885,000 after purchasing an additional 790,437 shares in the last quarter. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.